Palvella secures FDA grant for Phase III microcystic LMs treatment trial [Yahoo! Finance]
Ligand Pharmaceuticals Incorporated (LGND)
Last ligand pharmaceuticals incorporated earnings: 2/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ligand.com
Company Research
Source: Yahoo! Finance
of Orphan Products Development to support the Phase III SELVA trial of QTORIN 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations (microcystic LMs). Palvella's Phase III trial is one of only seven new studies to receive the funding out of 51 grant applications received for the fiscal year 2024. The Orphan Products Grants Program of the FDA provides grants every year to foster the development of medicines that could address the unmet needs of patients with rare diseases or conditions. Each grant application undergoes a rigorous review for scientific and technical merit by an independent panel of rare disease and regulatory experts. Consultation with the relevant FDA review division may also occur to assess whether the proposed study will yield data that could contribute to product approval. Since its inception, the FDA Orphan Products Grants Program funded clinical trials that have led to the approval of over 85 products. Palvella initiated the SELVA trial
Show less
Read more
Impact Snapshot
Event Time:
LGND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LGND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LGND alerts
High impacting Ligand Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
LGND
News
- Ligand to Present at Stifel 2024 Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Ligand to Present at Stifel 2024 Healthcare ConferenceBusiness Wire
- iMetabolic Biopharma Receives Second NIH Grant Award for Drug Discovery [Yahoo! Finance]Yahoo! Finance
- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Royal Bank of Canada from $130.00 to $140.00. They now have an "outperform" rating on the stock.MarketBeat
- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Benchmark Co. from $110.00 to $135.00. They now have a "buy" rating on the stock.MarketBeat
LGND
Earnings
- 11/7/24 - Beat
LGND
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form 144
- 11/8/24 - Form SC
- LGND's page on the SEC website